Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Jul 14

PMID 37446316

Authors

Hye Ryeon Choi

Kwangsoon Kim

Affiliations

Soon will be listed here.

Abstract

Although the overall prognosis of differentiated thyroid cancer (DTC), the most common endocrine malignancy, is favorable, a subset of patients exhibits aggressive features. Therefore, preclinical models that can be utilized to investigate DTC pathogenesis and novel treatments are necessary. Various mouse models have been developed based on advances in thyroid cancer genetics. This review focuses on recent progress in mouse models that have been developed to elucidate the molecular pathogenesis of DTC.

Citing Articles

Development of animal models to study aggressive thyroid cancers.

Dutta S, Knauf J Eur Thyroid J. 2025; 14(1).

PMID: 39874138 PMC: 11825169. DOI: 10.1530/ETJ-24-0361.

The Protective Role of Troxerutin (Trox) in Counteracting Anaplastic Thyroid Carcinoma (ATC) Progression.

Bova V, Basilotta R, Casili G, Lanza M, Filippone A, Campolo M Biomedicines. 2024; 12(8).

PMID: 39200219 PMC: 11351865. DOI: 10.3390/biomedicines12081755.

References

Masters J, Thomson J, Reid Y, Dirks W, PACKER P, Toji L . Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci U S A. 2001; 98(14):8012-7. PMC: 35459. DOI: 10.1073/pnas.121616198. View

Landa I, Knauf J . Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers. Endocrinol Metab (Seoul). 2019; 34(1):11-22. PMC: 6435851. DOI: 10.3803/EnM.2019.34.1.11. View

Charles R, Silva J, Iezza G, Phillips W, McMahon M . Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014; 12(7):979-86. PMC: 4635659. DOI: 10.1158/1541-7786.MCR-14-0158-T. View

Vossler M, Yao H, York R, Pan M, Rim C, Stork P . cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell. 1997; 89(1):73-82. DOI: 10.1016/s0092-8674(00)80184-1. View

Zhang L, Gaskins K, Yu Z, Xiong Y, Merino M, Kebebew E . An in vivo mouse model of metastatic human thyroid cancer. Thyroid. 2013; 24(4):695-704. PMC: 3993065. DOI: 10.1089/thy.2013.0149. View

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

Dobson M, Diallo-Krou E, Grachtchouk V, Yu J, Colby L, Wilkinson J . Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma. Endocrinology. 2011; 152(11):4455-65. PMC: 3199014. DOI: 10.1210/en.2011-1178. View

Ledent C, Dumont J, Vassart G, Parmentier M . Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 1992; 11(2):537-42. PMC: 556484. DOI: 10.1002/j.1460-2075.1992.tb05084.x. View

Chakravarty D, Santos E, Ryder M, Knauf J, Liao X, West B . Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011; 121(12):4700-11. PMC: 3225989. DOI: 10.1172/JCI46382. View

10.

Shimamura M, Nakahara M, Orim F, Kurashige T, Mitsutake N, Nakashima M . Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma. Endocrinology. 2013; 154(11):4423-30. DOI: 10.1210/en.2013-1174. View

11.

Burniat A, Jin L, Detours V, Driessens N, Goffard J, Santoro M . Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology. 2008; 149(10):5107-17. DOI: 10.1210/en.2008-0531. View

12.

Charles R, Iezza G, Amendola E, Dankort D, McMahon M . Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011; 71(11):3863-71. PMC: 3107361. DOI: 10.1158/0008-5472.CAN-10-4463. View

13.

Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P . Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-35. DOI: 10.1046/j.1365-2265.1999.00704.x. View

14.

Rochefort P, Caillou B, Michiels F, Ledent C, Talbot M, Schlumberger M . Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene. 1996; 12(1):111-8. View

15.

Antico-Arciuch V, Dima M, Liao X, Refetoff S, Di Cristofano A . Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene. 2010; 29(42):5678-86. PMC: 2967724. DOI: 10.1038/onc.2010.308. View

16.

Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M . RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009; 94(12):4735-41. DOI: 10.1210/jc.2009-1233. View

17.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

18.

Pringle D, Yin Z, Lee A, Manchanda P, Yu L, Parlow A . Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocr Relat Cancer. 2012; 19(3):435-46. PMC: 3667702. DOI: 10.1530/ERC-11-0306. View

19.

Kim S, Park Y, Schiff B, Doan D, Yazici Y, Jasser S . An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res. 2005; 11(5):1713-21. DOI: 10.1158/1078-0432.CCR-04-1908. View

20.

Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf J, Shah R . Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016; 126(3):1052-66. PMC: 4767360. DOI: 10.1172/JCI85271. View